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Abstract
Background: We compared the healing response of tibial delayed unions between subjects treated with low-
intensity pulsed ultrasound (LIPUS) (n = 51) and subjects treated with a sham device (n = 50). Fracture age was ≥
4 months in all cases. Study personnel and participants were blinded to random treatment assignment throughout
the study.
Methods: This multi-center randomized sham-controlled trial was undertaken at six hospitals in Germany. Adult
patients who had sustained a tibial shaft fracture that subsequently showed inadequate progress toward healing (i.
e., delayed union) were enrolled and randomized to receive either LIPUS (Exogen 2000/2000+, Smith & Nephew
GmbH, Schenefeld, Germany) or an identical nonoperative sham device. The daily treatment duration was 20
minutes, for a period of 16 weeks. Subjects randomly assigned to active treatment had the ultrasound pressure
wave signal set at the following parameters: 1.5 MHz frequency, 1 kHz repetition rate, 200 μs pulse duration, 30
mW/cm
2 spatial intensity. Progress toward healing was estimated from changes in bone mineral density (BMD) and
gap area as determined from computed tomography scans. Intention-to-treat analysis was conducted using a
multiple imputation methodology.
Results: Based on log-transformed data, mean improvement in BMD was 1.34 (90% confidence interval (CI) 1.14 to
1.57) times greater for LIPUS-treated subjects compared to sham (p = 0.002). A mean reduction in bone gap area
also favored LIPUS treatment (p = 0.014).
Conclusions: These findings demonstrate significantly greater progress toward bone healing after LIPUS treatment
compared to no LIPUS treatment in subjects with established delayed unions of the tibia.
Background
Low-intensity pulsed ultrasound (LIPUS) is a safe, non-
invasive treatment option that has been proven to
enhance the healing of fresh closed tibial fractures in a
Level-I randomized sham-controlled trial [1]. These
results have been corroborated in studies of complex
open fractures, prone to delayed union or nonunion
[2,3]. However, until recently, the specific mechanism of
action of LIPUS on the bone healing process remained
uncertain and a matter of intense speculation, discussion
and debate [4-6]. Using quantitative histomorphometric
analysis of biopsy samples from fibular delayed unions,
Rutten et al [7] reported that use of LIPUS accelerates
fracture healing by directly increasing bone formation
through increased osteoblastic activity. These authors
showed a demonstrable increase, compared to sham-
treated control patients, in osteoid thickness, mineral
apposition rate and bone volume at the leading edge of
new bony callus formation.
A number of positive single arm studies of LIPUS pro-
vides additional clinical evidence that the accelerated
healing achieved in fresh fractures can be extended to
the management of delayed unions and nonunions of
long bones [8-12]. However, due to ethical considera-
tions and difficulty in recruiting subjects, randomized
sham-controlled trials in this setting to definitively
demonstrate the value of LIPUS have been absent [6]. * Correspondence: jonblock@jonblockphd.com
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controlled trial of LIPUS in the treatment of delayed
unions of the tibia, offering Level-I evidence of effective-
ness. We tested the hypothesis that in comparison to a
placebo, 16 consecutive weeks of LIPUS treatment
would accelerate the progression to healing as evidenced
by quantitative radiographic measurements of bone
mineral density (BMD) and the reduction in the size of
the residual gap area.
Methods
Patients
A multi-center, randomized, controlled trial was under-
taken at six hospitals in Germany to determine the
effectiveness of LIPUS in accelerating the healing pro-
cess in delayed unions of the tibial shaft. All adult
patients who had sustained a tibial shaft fracture that
subsequently showed inadequate progress toward heal-
ing (i.e., delayed union) and provided informed consent
were candidates for inclusion in the study. Delayed
union was defined as lack of clinical and radiologic evi-
dence of union, bony continuity or bone reaction at the
fracture site for no less than 16 weeks from the index
injury or the most recent intervention [6,9,13]. Standard
anteroposterior (AP) and lateral radiographs were per-
formed at baseline to establish lack of union. Patients
were not admitted to the study if any of the following
criteria were present: pregnancy, revision or reopera-
tions at the fracture site within 16 weeks of enrollment,
deep wound infection, excessive malalignment. The trial
was approved by the institutional review boards at each
clinical site and was conducted in adherence to the
Declaration of Helsinki.
One hundred one subjects (age range: 14 to 70 years)
with delayed unions of the tibia, enrolled between Janu-
ary 2002 and December 2005, were randomly allocated
to treatment with either an active LIPUS device (n = 51)
or an inactive sham device (n = 50).
Interventions
Patients with established delayed unions of the tibia
were randomized to receive either LIPUS or an identical
nonoperative sham device. The study device was the
Exogen 2000/2000+ (Smith & Nephew GmbH, Schene-
feld, Germany). The sham device was inactivated in
such a manner as to be indistinguishable from the active
LIPUS device, except that it did not emit acoustic pres-
sure waves.
All subjects were instructed to use the device for 20
minutes per day, for 16 weeks. Those subjects randomly
assigned to active treatment had the ultrasound pressure
w a v es i g n a ls e ta tt h ef o l l o w i n gp a r a m e t e r s :1 . 5M H z
frequency, 1 kHz repetition rate, 200 μs pulse duration,
30 mW/cm
2 spatial intensity. All devices recorded the
amount of time per day of use as a means of assessing
subject compliance with the treatment protocol.
Treatment was assigned randomly to each subject on
a 1:1 basis in blocks of six and randomization was strati-
fied within each clinical site. The randomization code
was developed using a computer random number gen-
erator. The investigators, subjects and sponsor were
blinded to the random allocation sequence prior to
initiation of treatment and throughout the entire dura-
tion of this study. Once the study was complete and the
last subject reached 16 weeks of follow-up, the randomi-
zation code was broken and treatment assignments
revealed to the study statistician. Quantitative radio-
graphic assessments of BMD and gap area also were
undertaken without knowledge of treatment group
assignment.
Outcomes
The primary outcomes of this study were BMD and gap
area at the fracture site, assessed by computed tomogra-
phy (CT) scanning. All radiographic imaging studies
were evaluated at a central Radiology laboratory using a
dedicated workstation for image processing and digitiza-
tion. BMD was determined for three regions of interest:
fracture site, 2-3 mm proximal and distal. BMD also
was determined in a healthy reference area. For each of
the three regions, three replicate observations were
obtained. These three replicates were averaged to obtain
a mean BMD for each region separately for pre-treat-
ment and post-treatment evaluations. Region specific
changes from baseline were then computed. Finally, the
three region specific changes from baseline obtained for
each subject were averaged to obtain the primary effec-
tiveness endpoint defined as the mean change from
baseline in BMD.
BMD was indirectly estimated using the mean CT
attenuation coefficients, or Hounsfield units (HUs), for
each region of interest. Calibration to varying concentra-
tions of K2HPO4 to directly quantitate BMD in equiva-
lent mineral density (mg/cm
3) was not undertaken.
Thus, BMD results are reported in HUs [14,15]. Gap
area in mm
2 was estimated directly from CT scans
using digitized images.
The primary endpoint with respect to efficacy was
change in BMD between pre-treatment and 16 weeks.
Change in gap area at the fracture site was a secondary
endpoint.
AP and lateral radiographs also were taken at 1, 2 and
3 month follow-up intervals. Blinded to treatment
assignment, participating physicians were asked to judge
the healing status (healed/not healed) of each study sub-
ject at 16 weeks.
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All analyses employed Statistical Analysis Software
(SAS). Subject baseline characteristics were summarized
using frequency and percentage distributions or descrip-
tive statistics, as appropriate. Proportions were com-
pared using the Chi-square test with Yates’ continuity
correction or Fisher’s exact test. Continuous variables
were compared using the two sample t-test.
The primary analysis was intention-to-treat (ITT) and
involved all subjects who received random treatment
assignments and initiated device usage. Seventeen sub-
jects had missing post-treatment outcomes, conse-
quently 84 subjects were included in descriptive analyses
of ‘completers’. There was notable differential drop-out
between groups with 24% (12 of 50) of sham-treated
subjects and 9.8% (5 of 51) of active-treated subjects
missing post-treatment BMD values. The ITT cohort
was preserved by imputing missing clinical endpoints
using a multiple imputation procedure that minimizes
bias from differential drop-outs and properly accounts
for uncertainty in imputed values when performing sta-
tistical inference. Multiple imputation uses multiple pre-
dictions of missing clinical endpoints based on patient
characteristics and the baseline value of the clinical out-
come variables [16]. For each of five stochastically com-
pleted data sets, analysis of covariance (ANCOVA) was
used to estimate a treatment group contrast that con-
trolled for the baseline value of the clinical endpoint as
well as clinical site. This ANCOVA approach is consis-
tent with ICH E9 guidelines for statistical analysis of a
multi-site clinical trial [17]. The estimated group differ-
ence obtained for each of the five stochastically com-
pleted data sets were appropriately combined to obtain
a single estimate of the intervention effect. Attention
was paid to the validity of statistical model assumptions
using graphical and other approaches. We found that
BMD could be validly analyzed with or without log
transformation, but that valid inference required log
transformation for gap area. Analyses on log trans-
formed data expresses group differences in terms of
relative improvement which has a convenient clinical
interpretation. Estimates of relative and absolute group
differences were presented along with confidence inter-
vals that accounted for the multiple imputation.
All primary effectiveness results using statistical mod-
eling were based on a one-sided alpha = 0.05 with 90%
confidence intervals (CIs). Preliminary descriptive ana-
lyses without imputations and descriptive assessments of
effect size (ES) were two-sided with 95% CIs.
As specified ap r i o r i , study hypotheses were ordered
such that the hypothesis concerning change in BMD
was tested first. Only if the active device was shown to
be superior to sham based on a one-sided test at a =
0.05 would the second test regarding changes in bone
gap area be performed. This a priori ordering eliminated
the need to adjust significance levels for multiple testing.
The success rate for physician judgment of fracture
healing was compared between groups using Fisher’s
exact test. The statistical content of the manuscript was
approved by an expert in medical statistics and
epidemiology.
Results
Inspection of background characteristics between study
groups showed generally good balance achieved through
randomization (Table 1). Sham control subjects had a
greater average body mass index (p = 0.03). Addition-
ally, there was a larger percentage of LIPUS-treated sub-
jects with time since fracture ≥ 48 weeks (41% vs. 24%)
and a smaller percentage with < 24 weeks (14% vs.
30%), although this comparison did not achieve statisti-
cal significance (p = 0.08). Overall, compliance with the
treatment regimen was excellent, with a median total
time of device usage of 2040 minutes out of a possible
2240 minutes (91%).
Table 1 Background Characteristics by Study Group
Characteristic LIPUS Control
(n = 51) (n = 50) P Value
Age, mean ± SD, y 42.6 ±
14.6
45.1 ±
11.9
0.35
Female, n (%) 15 (29) 9 (18) 0.24
Body Mass Index, mean ± SD, kg/
m
2
25.1 ± 4.0 27.1 ± 5.0 0.03
Fracture Age, mean ± SD, weeks 60.3 ±
61.0
46.4 ±
41.7
0.18
Distribution of Fracture Age, n (%)
< 24 weeks
24 to < 36 weeks
36 to < 48 weeks
≥ 48 weeks
7 (14)
16 (32)
7 (14)
21 (41)
15 (30)
12 (24)
11 (22)
12 (24)
0.08
Mechanism of Injury*, n (%)
High-energy trauma
Low-energy trauma
26 (52)
24 (47)
26 (52)
24 (28)
1.00
Open Fracture, n (%) 16 (31) 22 (44) 0.40
Surgical Treatment
†, n (%)
Intramedullary nail
‡
Locking screws
External fixation
Osteosynthesis plate
Supplemental bone graph
29 (58)
20 (39)
16 (31)
19 (37)
17 (33)
24 (49)
14 (28)
18 (36)
19 (38)
13 (26)
0.42
0.29
0.68
1.00
0.52
Smoking Status, n (%)
Non smoker
Ex-smoker
Current smoker
20 (39)
12 (24)
19 (37)
15 (30)
12 (24)
23 (46)
0.57
* One missing value LIPUS.
† One missing value each, LIPUS and Control.
‡ Includes primary and any follow-up procedures.
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observed cases are expressed on the log scale in order
to allow comparison of ES between BMD and gap area.
The mean (SD) changes from pre-treatment to 16 weeks
follow-up in log BMD were 0.87 (0.67) HU and 0.57
(0.38) HU for active- and sham-treated groups, respec-
tively (t-test, p = 0.014) (Figure 1). The difference in
these means, divided by the pooled standard deviation
results in a standardized ES of 0.53 (95% CI 0.09 to
0.97). The corresponding mean changes (SD) in log gap
area were -0.131 (0.072) mm
2 and -0.097 (0.070) mm
2
for active and sham groups, respectively (p = 0.034)
resulting in a standardized effect size of comparable
absolute value (ES = -0.47, 95% CI -0.91 to -0.03).
Following multiple imputation, the adjusted difference
between active and sham study groups in the mean
change in BMD was 122.4 HUs (90% CI 42.1 to 202.7).
The null hypothesis of equal group mean changes in
BMD was rejected with p = 0.007 (1-sided ANCOVA
after multiple imputation).
Based on log transformed data, the adjusted mean
improvement in BMD was 1.34 (90% CI 1.14 to 1.57)
times greater for LIPUS-treated subjects compared to
sham controls (p = 0.002).
A statistically significant benefit of LIPUS treatment
also was realized in terms of mean reduction in bone
gap area based on log transformed data using multiple
imputation methods (1-sided, p = 0.014). The exponen-
tiated difference in log mean changes was 0.974 (90% CI
0.956 to 0.993) reflecting proportionally smaller average
gap area. For untransformed data, the group difference
in mean adjusted changes from baseline in bone gap
area was -0.457 mm
2 (90% CI -0.864 to -0.049) with 1-
sided p = 0.03 similarly reflecting a smaller expected
gap area in LIPUS-treated subjects compared to
controls.
Post-treatment log BMD group differences were evalu-
ated while controlling for baseline and other indepen-
dent predictors using multiple regression analysis.
Results demonstrated that the relative effectiveness of
LIPUS remained statistically significant (p = 0.004) with
negligible change in magnitude. After exponentiating
the relevant parameter estimates, the adjusted mean
BMD was found to be 1.35 (95% CI 1.10 to 1.65) times
larger among patients treated with LIPUS compared to
those treated with sham, which is nearly identical to the
value obtained without covariate adjustment. Other
independent variables entering this model at a statisti-
cally significant level included pre-treatment log BMD
(ratio = 0.64, 95% CI 0.55 to 0.74, p < 0.0001), time
since fracture < 48 weeks (ratio = 1.33, 95% CI 1.08 to
1.65, p = 0.009), and use of intramedullary nail fixation
(ratio = 1.23, 95% CI 1.00 to 1.5, p = 0.047). For exam-
ple, controlling for LIPUS status and these other vari-
ables, the (geometric) mean BMD was found to be 1.33
times larger for patients with a time since fracture < 48
weeks compared to 48 weeks or greater. Similarly, use
of intramedullary nail fixation increases the predicted
week 16 mean BMD by a factor of 1.23 (95% CI 1.00 to
1.50). Overall, the model accounted for approximately
41% of the variability in post-treatment log BMD. A
time since injury by study group interaction added to
this model was not significant (p = 0.76) suggesting that
the bone growth benefit of LIPUS was present whether
or not the time since fracture was 48 weeks or greater,
despite the independent effects of time since fracture.
At the completion of the 16 week study period, 65%
(33 of 51) of LIPUS and 46% (23 of 50) of sham subjects
were judged to be healed by the participating physicians
(p = 0.07). There were no device-related adverse events
in this study group.
Discussion
The prevalence of delayed union following tibial fracture
has been estimated to be 4.4% [13]. Delayed unions,
which often evolve into nonunions, can result in signifi-
cant morbidity, functional impairment and loss of qual-
ity of life for the afflicted patient. Additional surgical
Figure 1 Line graph illustrating improvement in bone mineral
density for each treatment group separately through 16 weeks
of follow-up. Data based on ‘completers’ analysis of observed
cases. The difference in mean improvements in log Hounsfield units
was statistically significant (p = 0.014) with a corresponding effect
size, 0.53, representing a medium degree of effectiveness.
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bone growth factors are routinely required to assure
healing once a nonunion is evident. These procedures
are complex and costly [18]. There is consensus based
on several systematic reviews and meta-analyses that use
of LIPUS accelerates the healing of fresh fractures
[5,19-21], and offers a cost-effective addition to conser-
vative or operative management of these injuries [22].
The results of the current randomized controlled trial
extend the positive findings of LIPUS treatment in fresh
fractures and establish the effectiveness of this non-inva-
sive modality in delayed unions of the tibia. This is the
first study to offer Level-I evidence of this effect in a
single fracture type. The primary conclusion from our
efficacy analysis using multiple imputation was that the
estimated increase in BMD among subjects randomized
to active LIPUS treatment was 34% larger than among
subjects randomized to receive sham treatment. The
computed effect size based on the ‘completers’ cohort
was 0.53 (95% CI 0.09 to 0.97) representing a medium
degree of effectiveness [23]. Use of LIPUS also resulted
in a significantly smaller residual gap area at the fracture
site compared to sham treatment with comparable abso-
lute magnitude of effectiveness (ES = -0.47, 95% CI
-0.91 to -0.03). Multiple imputation was used to con-
struct primary ITT assessments of relative effectiveness
that allowed inclusion of all randomized subjects with
comparable results. From these analyses it was estimated
that the expected BMD at week 16 to be 1.34 (90% CI
1.14 to 1.57) times larger among patients treated with
LIPUS compared to those treated with sham. Nearly
identical results were obtained after controlling for
other significant baseline covariates.
These findings have important implications for the
management of tibial delayed unions and nonunions as
these injuries account for 35% to 65% of all nonunions
[24]. Also noteworthy, was the finding that long times
since fracture (e.g., ≥ 48 weeks) were associated with
poorer radiographic outcomes independent of treatment
group. This relationship has been shown previously [9]
and underscores the need to initiate LIPUS treatment at
the earliest interval when delayed union is suspected.
The institutional review boards at the participating
clinical centers limited the study to 16 weeks for ethical
reasons. It is unlikely that most established delayed
unions will heal completely in this time frame or show
discernible improvement in patient reported outcomes
[13]. Therefore, we measured progression to healing
using surrogate measures of healing, BMD and gap
area, because efficacy with LIPUS had previously been
established in a Level-I randomized controlled trial of
fresh long bone fractures [1] as well as in delayed
unions and nonunions reported in a large patient regis-
try [5,10], and in several single arm studies [8-12].
Indeed, quantitative CT measurements of BMD in tibial
fracture models have been shown to be strongly asso-
ciated with several indices of biomechanical and struc-
tural integrity indicative of the repair and healing
processes [25,26].
Conclusions
In conclusion, this trial provides Level-I evidence that
use of LIPUS accelerates the healing process and likely
improves the odds of achieving solid union in patients
with delayed unions of the tibia. These positive findings
should assist in establishing this non-invasive modality
as a viable, effective treatment option for patients suffer-
ing these injuries.
Acknowledgements
The authors are most grateful for the biostatistical support provided by Greg
Maislin, Ph.D. We also wish to acknowledge the clinical sites in Duisburg,
Goerlitz, Hamburg, Jena, Ludwigshafen and Ulm, Germany for recruiting and
enrolling subjects into this trial.
Author details
1Department of Orthopaedics, University Hospital Marburg, Baldingerstrasse,
35043 Marburg, Germany.
22210 Jackson Street, Suite 401, San Francisco, CA
94115, USA.
3Department of Trauma, Hand, and Reconstructive Surgery,
University of Ulm, Steinhövelstrasse 9, 89075 Ulm, Germany.
Authors’ contributions
All authors read and approved the final manuscript. MS, JA and AS
conceived of the study and participated in its design. JB had the primary
role of interpreting the data analysis and authoring the manuscript. MS, JA
and AS assisted in revising the manuscript for important intellectual content.
Competing interests
This study was supported, in part, by Smith & Nephew (Memphis, TN). JB is
an independent consultant and received remuneration from the sponsor to
assist in the development of the manuscript. The other authors declare that
they have no competing interests.
Received: 12 May 2010 Accepted: 8 October 2010
Published: 8 October 2010
References
1. Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF: Acceleration of
tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J
Bone Joint Surg Am 1994, 76:26-34.
2. Gold SM, Wasserman R: Preliminary results of tibial bone transports with
pulsed low intensity ultrasound (Exogen). J Orthop Trauma 2005, 19:10-16.
3. Leung KS, Lee WS, Tsui HF, Liu PP, Cheung WH: Complex tibial fracture
outcomes following treatment with low-intensity pulsed ultrasound.
Ultrasound Med Biol 2004, 30:389-395.
4. Einhorn TA: Enhancement of fracture-healing. J Bone Joint Surg Am 1995,
77:940-956.
5. Rubin C, Bolander M, Ryaby JP, Hadjiargyrou M: The use of low-intensity
ultrasound to accelerate the healing of fractures. J Bone Joint Surg Am
2001, 83-A:259-270.
6. Romano CL, Romano D, Logoluso N: Low-intensity pulsed ultrasound for
the treatment of bone delayed union or nonunion: a review. Ultrasound
Med Biol 2009, 35:529-536.
7. Rutten S, Nolte PA, Korstjens CM, van Duin MA, Klein-Nulend J: Low-
intensity pulsed ultrasound increases bone volume, osteoid thickness
and mineral apposition rate in the area of fracture healing in patients
with a delayed union of the osteotomized fibula. Bone 2008, 43:348-354.
8. Gebauer D, Mayr E, Orthner E, Ryaby JP: Low-intensity pulsed ultrasound:
effects on nonunions. Ultrasound Med Biol 2005, 31:1391-1402.
Schofer et al. BMC Musculoskeletal Disorders 2010, 11:229
http://www.biomedcentral.com/1471-2474/11/229
Page 5 of 69. Jingushi S, Mizuno K, Matsushita T, Itoman M: Low-intensity pulsed
ultrasound treatment for postoperative delayed union or nonunion of
long bone fractures. J Orthop Sci 2007, 12:35-41.
10. Mayr E, Frankel V, Ruter A: Ultrasound–an alternative healing method for
nonunions? Arch Orthop Trauma Surg 2000, 120:1-8.
11. Nolte PA, van der Krans A, Patka P, Janssen IM, Ryaby JP, Albers GH: Low-
intensity pulsed ultrasound in the treatment of nonunions. J Trauma
2001, 51:693-702, discussion 702-693.
12. Rutten S, Nolte PA, Guit GL, Bouman DE, Albers GH: Use of low-intensity
pulsed ultrasound for posttraumatic nonunions of the tibia: a review of
patients treated in the Netherlands. J Trauma 2007, 62:902-908.
13. Phieffer LS, Goulet JA: Delayed unions of the tibia. J Bone Joint Surg Am
2006, 88:206-216.
14. Shapurian T, Damoulis PD, Reiser GM, Griffin TJ, Rand WM: Quantitative
evaluation of bone density using the Hounsfield index. Int J Oral
Maxillofac Implants 2006, 21:290-297.
15. Spruit M, Meijers H, Obradov M, Anderson PG: CT density measurement of
bone graft within an intervertebral lumbar cage: increase of hounsfield
units as an indicator for increasing bone mineral content. J Spinal Disord
Tech 2004, 17:232-235.
16. Rubin DB, Schenker N: Multiple imputation in health-care databases: an
overview and some applications. Stat Med 1991, 10:585-598.
17. ICH Harmonised Tripartite Guideline. Statistical principles for clinical
trials. International Conference on Harmonisation E9 Expert Working
Group. Stat Med 1999, 18:1905-1942.
18. Kanakaris NK, Giannoudis PV: The health economics of the treatment of
long-bone non-unions. Injury 2007, 38(Suppl 2):S77-84.
19. Busse JW, Bhandari M, Kulkarni AV, Tunks E: The effect of low-intensity
pulsed ultrasound therapy on time to fracture healing: a meta-analysis.
CMAJ 2002, 166:437-441.
20. Malizos KN, Hantes ME, Protopappas V, Papachristos A: Low-intensity
pulsed ultrasound for bone healing: an overview. Injury 2006, 37(Suppl
1):S56-62.
21. Walker NA, Denegar CR, Preische J: Low-intensity pulsed ultrasound and
pulsed electromagnetic field in the treatment of tibial fractures: a
systematic review. J Athl Train 2007, 42:530-535.
22. Heckman JD, Sarasohn-Kahn J: The economics of treating tibia fractures.
The cost of delayed unions. Bull Hosp Jt Dis 1997, 56:63-72.
23. Cohen J: Statistical power analysis for the behavioral sciences. Hillsdale,
N.J.: Lawrence Earlbum Associates, 2 1988.
24. Dickson K, Katzman S, Delgado E, Contreras D: Delayed unions and
nonunions of open tibial fractures. Correlation with arteriography
results. Clin Orthop Relat Res 1994, 189-193.
25. Augat P, Merk J, Genant HK, Claes L: Quantitative assessment of
experimental fracture repair by peripheral computed tomography. Calcif
Tissue Int 1997, 60:194-199.
26. Markel MD, Morin RL, Wikenheiser MA, Lewallen DG, Chao EY: Quantitative
CT for the evaluation of bone healing. Calcif Tissue Int 1991, 49:427-432.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2474/11/229/prepub
doi:10.1186/1471-2474-11-229
Cite this article as: Schofer et al.: Improved healing response in delayed
unions of the tibia with low-intensity pulsed ultrasound: results of a
randomized sham-controlled trial. BMC Musculoskeletal Disorders 2010
11:229.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schofer et al. BMC Musculoskeletal Disorders 2010, 11:229
http://www.biomedcentral.com/1471-2474/11/229
Page 6 of 6